Medtide Inc. Announces Acceptance of H Share Full Circulation Plan Application by China Securities Regulatory Commission

Reuters

2025/07/27

Medtide Inc. Announces Acceptance of H Share Full Circulation Plan Application by <a href="https://laohu8.com/S/601066">China Securities</a> Regulatory Commission

Medtide Inc., a joint stock company incorporated in the People's Republic of China, has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation Plan. This regulatory acceptance pertains to the conversion of 68,201,112 unlisted shares into H shares, each with a par value of RMB1.0. This development is a significant step towards the proposed implementation of the full circulation of H shares for certain shareholders of the company. The conversion and listing process will still require adherence to additional procedures mandated by the CSRC, the Hong Kong Stock Exchange, and other relevant regulatory authorities. Medtide Inc. has advised shareholders and potential investors to exercise caution when dealing in the company's securities. Further announcements will be made as details of the conversion and listing are finalized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtide Inc. published the original content used to generate this news brief on July 27, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2554748842"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554748842\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554748842?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-27 18:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554748842","market":"nz","top_or_hot":-1,"title":"Medtide Inc. Announces Acceptance of H Share Full Circulation Plan Application by China Securities Regulatory Commission","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medtide Inc. Announces Acceptance of H Share Full Circulation Plan Application by <a href=\"https://laohu8.com/S/601066\">China Securities</a> Regulatory Commission\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Medtide Inc., a joint stock company incorporated in the People's Republic of China, has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation Plan. This regulatory acceptance pertains to the conversion of 68,201,112 unlisted shares into H shares, each with a par value of RMB1.0. This development is a significant step towards the proposed implementation of the full circulation of H shares for certain shareholders of the company. The conversion and listing process will still require adherence to additional procedures mandated by the CSRC, the <a href=\"https://laohu8.com/S/HKRHF\">Hong Kong</a> Stock Exchange, and other relevant regulatory authorities. Medtide Inc. has advised shareholders and potential investors to exercise caution when dealing in the company's securities. Further announcements will be made as details of the conversion and listing are finalized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtide Inc. published the original content used to generate this news brief on July 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medtide Inc. Announces Acceptance of H Share Full Circulation Plan Application by China Securities Regulatory Commission</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedtide Inc. Announces Acceptance of H Share Full Circulation Plan Application by China Securities Regulatory Commission\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-27 18:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medtide Inc. Announces Acceptance of H Share Full Circulation Plan Application by <a href=\"https://laohu8.com/S/601066\">China Securities</a> Regulatory Commission\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Medtide Inc., a joint stock company incorporated in the People's Republic of China, has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation Plan. This regulatory acceptance pertains to the conversion of 68,201,112 unlisted shares into H shares, each with a par value of RMB1.0. This development is a significant step towards the proposed implementation of the full circulation of H shares for certain shareholders of the company. The conversion and listing process will still require adherence to additional procedures mandated by the CSRC, the <a href=\"https://laohu8.com/S/HKRHF\">Hong Kong</a> Stock Exchange, and other relevant regulatory authorities. Medtide Inc. has advised shareholders and potential investors to exercise caution when dealing in the company's securities. Further announcements will be made as details of the conversion and listing are finalized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtide Inc. published the original content used to generate this news brief on July 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03880","symbol_name":"泰德医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250727:nNDLb80D2T:1","article_id":"2554748842","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554748842","pubTimestamp":1753611935,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medtide Inc., a joint stock company incorporated in the People's Republic of China, has announced that the China Securities Regulatory Commission  has accepted its application for the H Share Full Circulation Plan. This regulatory acceptance pertains to the conversion of 68,201,112 unlisted shares into H shares, each with a par value of RMB1.0. This development is a significant step towards the proposed implementation of the full circulation of H shares for certain shareholders of the company. The conversion and listing process will still require adherence to additional procedures mandated by the CSRC, the Hong Kong Stock Exchange, and other relevant regulatory authorities. Medtide Inc. has advised shareholders and potential investors to exercise caution when dealing in the company's securities. Further announcements will be made as details of the conversion and listing are finalized.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligenc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03880":"泰德医药"},"translate_title":"Medtide Inc.宣布中国证监会受理H股全流通计划申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03880":0.9},"content_text":"Medtide Inc. Announces Acceptance of H Share Full Circulation Plan Application by China Securities Regulatory Commission\n    \n\n        Medtide Inc., a joint stock company incorporated in the People's Republic of China, has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation Plan. This regulatory acceptance pertains to the conversion of 68,201,112 unlisted shares into H shares, each with a par value of RMB1.0. This development is a significant step towards the proposed implementation of the full circulation of H shares for certain shareholders of the company. The conversion and listing process will still require adherence to additional procedures mandated by the CSRC, the Hong Kong Stock Exchange, and other relevant regulatory authorities. Medtide Inc. has advised shareholders and potential investors to exercise caution when dealing in the company's securities. Further announcements will be made as details of the conversion and listing are finalized.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtide Inc. published the original content used to generate this news brief on July 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}